Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Thoracic 3Head & Neck 2Genitourinary 1Endocrine 1Classical hematology 1Breast 1

Conditions

Neuroendocrine Tumors 531Multiple Endocrine Neoplasia Type 1 187Pituitary Neoplasms 186Thyroid Cancer, Papillary 178Pheochromocytoma 152Carcinoma, Neuroendocrine 140Thyroid Neoplasms 130Neoplasms 107Carcinoid Tumor 99Paraganglioma 98Adrenocortical Carcinoma 92Thyroid Carcinoma, Anaplastic 82Pancreatic Neoplasms 69Neoplasm Metastasis 67Insulinoma 61Adrenal Gland Neoplasms 61Gastro-enteropancreatic neuroendocrine tumor 58Carcinoma, Medullary 58Adenocarcinoma, Follicular 58Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 56Adenoma, Islet Cell 56Lung Neoplasms 50Sarcoma 49Colorectal Neoplasms 49Carcinoma, Renal Cell 49Melanoma 47Small Cell Lung Carcinoma 45Prostatic Neoplasms 44Head and Neck Neoplasms 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Substance-Related Disorders × Endocrine × Clear all
NCT02358226 2020-02-17

HIV & Drug Abuse Prevention for South African Men

University of California, Los Angeles

Phase 3 Completed
1,211 enrolled
Endocrine

Acquired Immunodeficiency Syndrome, Alcoholism, Multiple Endocrine Neoplasia Type 1, Substance-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡